1700003F12Rik Activators
C2orf81 homolog protein activators encompass a diverse array of chemical compounds that can enhance the protein's functional activity through several unique signaling pathways. Forskolin, by increasing intracellular cAMP levels, indirectly enhances the C2orf81 homolog protein's function via cAMP-dependent PKA activation, which may lead to the phosphorylation of substrates that interact with or regulate the C2orf81 homolog protein. Similarly, 8-Bromo-cAMP serves as a stable cAMP analog, also activating PKA and potentially promoting phosphorylation processes that amplify the C2orf81 homolog protein's activity. Hemoglobin activators comprise a series of chemical compounds that enhance the oxygen-carrying capacity and overall function of Hemoglobin through various biochemical pathways. Hydroxycarbamide and Hydroxyurea, for instance, increase the proportion of fetal hemoglobin in the bloodstream, which binds oxygen more readily than its adult counterpart, thus indirectly enhancing oxygen transport by Hemoglobin.
The phosphodiesterase inhibitor Isobutylmethylxanthine and the aldehyde Benzaldehyde both work to increase the oxygen affinity of Hemoglobin; the former by elevating cAMP, which can influence Hemoglobin's quaternary structure and function, and the latter through chemical modification of Hemoglobin's amino groups. Similarly, 5-Hydroxymethyl-2-furaldehyde stabilizes Hemoglobin's relaxed state, promoting greater oxygen uptake. Sodium nitrite participates in nitric oxide-mediated vasodilation, potentially enhancing the delivery of oxygen to tissues. Cobalt(II) chloride and Dimethyloxalylglycine operate upstream by increasing erythropoietin levels, leading to higher Hemoglobin production. Bezafibrate and Resveratrol, although not direct activators, contribute to increased Hemoglobin levels by influencing gene expression and red blood cell longevity, respectively.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $106.00 $166.00 $289.00 $550.00 $819.00 | 2 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that is resistant to degradation by phosphodiesterases. It activates PKA, which could lead to the phosphorylation of the C2orf81 homolog protein, potentially enhancing its biological functions within the cell. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate is a signaling sphingolipid that activates sphingosine-1-phosphate receptors, leading to downstream signaling events. Activation of these pathways can influence the functional activity of the C2orf81 homolog protein by modulating membrane-associated signaling domains. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium/calmodulin-dependent protein kinases. This activation can indirectly enhance the activity of the C2orf81 homolog protein through calcium-dependent signaling mechanisms. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific protein kinase C (PKC) inhibitor. By selectively inhibiting PKC, the compound could shift the balance of cellular signaling toward pathways that activate the C2orf81 homolog protein. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG is an Hsp90 inhibitor that can disrupt protein folding and stability. By inhibiting Hsp90, it could lead to the stabilization and activation of client proteins that interact with or regulate the C2orf81 homolog protein. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of proteins. This could lead to the accumulation and enhanced activity of the C2orf81 homolog protein if it is normally regulated by proteasomal degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway. Inhibition of this pathway might reduce negative feedback loops and enable activation of alternative pathways that enhance the activity of the C2orf81 homolog protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor that prevents the activation of MAPK/ERK signaling. By inhibiting this pathway, the compound could activate compensatory pathways that lead to the enhancement of the C2orf81 homolog protein's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that leads to changes in cytoskeletal dynamics. This inhibition may enhance signaling pathways that are involved in the regulation of the C2orf81 homolog protein. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases can lead to increased phosphorylation levels of proteins and may indirectly enhance the activity of the C2orf81 homolog protein. | ||||||